The pharmaceutical company Sanofi has reduced its supply of flu vaccines to Ukraine during the current epidemic season, delivering 100,000 doses with no additional deliveries planned.
According to information provided to Interfax-Ukraine by the pharmaceutical company, it supplied 250,000 doses to Ukraine during the previous epidemic season.
“The reduction in deliveries of Sanofi influenza vaccines this season is due to temporary difficulties in production processes, including the company’s global transition to the production of trivalent vaccines in accordance with updated WHO recommendations. The adaptation of technological and logistical processes is currently underway, which has temporarily affected the volume of vaccine supplies to countries in the northern hemisphere, including Ukraine. No additional vaccine supplies are expected this year,” the company said.
In addition, the company reported that Sanofi’s quadrivalent influenza vaccine, which was imported in the amount of 100,000 doses, remains the only vaccine registered by the Ministry of Health in Ukraine for the 2025/2026 epidemic season.
Currently, the media and social networks are reporting a significant shortage of flu vaccines during the current epidemic season. Private clinics are reporting that it is impossible to purchase the vaccine.
The Interfax-Ukraine agency is awaiting comments on the vaccine situation during the current epidemic season from the Ministry of Health, the State Emergency Service, and the State Service of Ukraine on Medicines and Drugs Control.
As reported, as of the end of September 2025, the State Medical Service announced that the first 76,000 doses of the Korean vaccine GC FLU, manufactured by GC BioPharma Corp. and imported by Biolabs LLC, had passed quality control. The quality control procedure was also passed by 100,000 doses of the French vaccine VAXIGRIP TETRA, manufactured by Sanofi Pasteur and imported by Sanofi-Aventis Ukraine LLC. In early October, Biolabs LLC planned to import another 54,000 doses of the GC Flu vaccine manufactured by GC Biopharma Corp.
